Acosta JN, Falcone GJ, Rajpurkar P, Topol EJ. Multimodal biomedical AI. Nat Med. 2022 Sep;28(9):1773-1784.
 
AIFA 2023. Criticità etiche e normative nel trattamento dei dati personali sanitari nella ricerca osservazionale.
https://www.aifa.gov.it/documents/20142/1808580/Criticita_etiche_ricerca_osservazionale_06.04.2023.pdf [accesso del 04/02/2024]
 
AIFA. Valutazioni economiche. https://www.aifa.gov.it/valutazioni-economiche [accesso del 04/02/2024]
Aiyegbusi OL, Cruz Rivera S, Roydhouse J, Kamudoni P, Alder Y,Anderson N, Baldwin RM, Bhatnagar V, Black J, Bottomley A, Brundage M, Cella D, Collis P, Davies EH, Denniston AK, Efficace F, Gardner A, Gnanasakthy A, Golub RM, Hughes SE, Jeyes F, Kern S, King-Kallimanis BL, Martin A, McMullan C, Mercieca-Bebber R, Monteiro J, Peipert JD, Quijano-Campos JC, Quinten C, Rantell KR, Regnault A, Sasseville M, Schougaard LMV,Sherafat-Kazemzadeh R, Snyder C, Stover AM, Verdi R, Wilson
R, Calvert MJ. Recommendations to address respondent burden associated with patient-reported outcome assessment. Nat Med.2024 Feb 29.
 
AlphaFord. https://deepmind.google/technologies/alphafold/ [accesso del 04.02.2024]
 
AIRC 2020. I big data nella ricerca sul cancro. https://www.airc. it/news/big-data-ricerca-cancro [accesso del 04.02.2024]
 
Arlett P, Kjaer J, Broich K, Cooke E. Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value. Clin Pharmacol Ther. 2022 Jan;111(1):21-23.
 
AMGEN. Follow the Data https://www.amgen.com/stories/2022/10/follow-the-data#:~:text=SCIENCE%20
%26%20INNOVATION%2010,take%20years%20to%20complete%20enrollment [accesso del 04.02.2024]
 
Auffray C, et al. Making sense of big data in health research:Towards an EU action plan. Genome Med. 2016 Jun 23;8(1):71.Erratum in: Genome Med. 2016 Nov 7;8(1):118.
 
Berdud M, Drummond M, Towse A. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020 Sep4;18:31.
 
Big Data for Better Outcomes - BD4BO. https://bd4bo.eu/index.php/why-bd4bo/project-summary/ [accesso del 04.02.2024]
 
Bergenstråhle L, He B, Bergenstråhle J, et al. Super-resolved spatial transcriptomics by deep data fusion. Nat Biotechnol.2022 Apr;40(4):476-479.
 
Bhinder B, Gilvary C, Madhukar NS, Elemento O. Artificial Intelligence in Cancer Research and Precision Medicine. Cancer Discov.2021 Apr;11(4):900-915.
 
Boehm KM, Khosravi P, Vanguri R, et al. Harnessing multimodal data integration to advance precision oncology. Nat Rev Cancer. 2022 Feb;22(2):114-126.
 
Bray B, Ramagopalan SV. R WE ready for reimbursement? Around up of developments in real-world evidence relating to health technology assessment: part 11. J Comp Eff Res. 2023 May;12(5):e230008.
 
Bullement A, Podkonjak T, Robinson MJ, Benson E, Selby R, Hatswell AJ, Shields GE. Real-world evidence use in assessments of cancer drugs by NICE. Int J Technol Assess Health Care. 2020
Jul 10:1-7.
 
CADTH 2023. Guidance for Reporting Real-World Evidence.https://www.cadth.ca/guidance-reporting-real-world-evidence [accesso del 04.02.2024]
 
Carmi L, Zohar M, Riva GM. The EuropeanGeneral Data Protection Regulation(GDPR) in mHealth: Theoretical and practical aspects for practitioners’ use. Med Sci Law. 2023
Jan;63(1):61-68.
 
Castelo-Branco L, Pellat A, Martins-Branco D, Valachis A, Derksen JWG,Suijkerbuijk KPM, Dafni U, Dellaporta T, Vogel A, PrelajA, Groenwold RHH, Martins H, Stahel R, Bliss J, Kather J, Ribelles
N, Perrone F, Hall PS, Dienstmann R, Booth CM, Pentheroudakis G, Delaloge S, Koopman M. ESMO Guidance for Reporting Oncology real-World evidence(GROW). Ann Oncol. 2023 Dec;34(12):1097-1112.
 
Cavazza M., Costa F., Jommi C. (a cura di), L’organizzazione e la gestione delle sperimentazioni cliniche, 2016, Egea, Milano.
 
Center For Cancer Research(CCR). Big Data and Artificial Intelligence. https://ccr.cancer.gov/news/horizons/article/big-data [accesso del 04.02.2024]
 
Centro studi FADOI 2019. Libro Bianco sulla ricerca clinica indipendente: dalle fonti di finanziamento al valore etico e sociale. https://www.fondazioneroche.it/libro-bianco-per-la-ricerca-indipendente/[accesso del 04.02.2024]
 
Chen RJ, Lu MY, Williamson DFK, et al. Pan-cancer integrative histology-genomic analysis via multimodal deep learning. Cancer Cell. 2022 Aug 8;40(8):865-878.e6.
 
Chhina A, Trehan K, Saini M, Thakur S, Kaur M, Shahtaghi NR, Shivgotra R, Soni B, Modi A, Bakrey H, Jain SK. Revolutionizing Pharmaceutical Industry: The Radical Impact of ArtificialIntelligence and Machine Learning. Curr Pharm Des. 2023;29(21):1645-1658.
 
Cicchetti A, Addesso D, Leone FE, Amato A, Angerame L, D’Aversa A, Fraticelli M, Nicora C, Sfreddo E, Fumarola M, Porcino R, Cocciolo G, Re S, Scaccabarozzi S. Valorization of clinical trials from the ItalianNational Health Service perspective: definition and first application of a model to estimate avoidedcosts. Glob Reg Health Technol Assess. 2020 Jun 16;7:26-32.
 
Clinical Trial Center. Fondazione Policlinico Universitario Agostino Gemelli IRCCS. https://clinicaltrialcenter.it/ [accesso del 04/02/2024]
 
Consiglio Superiore di Sanita’(CSS) 2020. Trasferimento delle tecniche omiche nella pratica clinica. www.salute.gov.it/imgs/C_17_pubblicazioni_3093_allegato.pdf [accesso del 04.02.2024]
 
Crispin-Ortuzar M, et al. Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer. Nat Commun. 2023 Oct 24;14(1):6756.
 
Data (RWD) quality and Real World Evidence(RWE) use. https:// www.ema.europa.eu/en/documents/report/report-multi-stakeholder-workshop-real-world-data-rwd-quality-and-real-world-evidence-rwe-use_en.pdf [accesso del 04.02.2024]
 
Efficace F, Breccia M, Fazi P, Cottone F,Holzner B, Vignetti M.The GIMEMA-ALLIANCE Digital Health Platform for Patients WithHematologic Malignancies in the COVID-19 Pandemic and Postpandemic Era: Protocol for a Multicenter, Prospective, Observational Study. JMIR Res Protoc. 2021 Jun 1;10(6):e25271.
 
Efficace F, Patriarca A, Luppi M, Potenza L, Caocci G, Tafuri A, Fazio F, Cartoni C, Petrucci MT, Carmosino I, Moia R, Margiotta Casaluci G, Boggione P, Colaci E, Giusti D, Pioli V, Sparano F, Cottone F, De Fabritiis P, Ardu NR, Niscola P, Capodanno I, Leporace AP, Pelliccia S, Lugli E, La Sala E, Rigacci L, Santopietro M, Fozza C, Siragusa S, Breccia M, Fazi P, Vignetti M. Physicians’ Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology
Practice. Evidence From the GIMEMA-ALLIANCE Platform. FrontOncol. 2022 Mar 17;12:826040.
 
Efficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G, Bonifacio M, Patriarca A, Capodanno I, Miggiano MC, Tiribelli M, Breccia M, Luciano L, Giai V, Iurlo A, Abruzzese E, Fava C, Dinner S, Altman JK, Rosti G, Cortes J, Vignetti M, Cella D. Patient-reported symptom monitoring and adherence to therapy in patients withnewly diagnosed chronic myeloid leukemia. Cancer. 2024 Jan;130(2):287-299.
 
EHDS - European Health Data Space. https://health.ec.europa. eu/ehealth-digital-health-and care/european-health-data-space_en[accesso del 04.02.2024]
 
EFPIA 2023. PatientsW.A.I.T. Indicator 2022 Survey. https:// www.efpia.eu/media/s4qf1eqo/efpia_patient_wait_indicator_final_report.pdf [accesso del 11.03.2024]
 
EMA - Big Data. https://www.ema.europa.eu/en/about-us/how-we-work/big-data [accesso del 04.02.2024]
 
EMA 2023. Report from “Multi-stakeholder workshop on Real World
 
EMA 2021. AI, Digital Twins and the promise of personalized medicine. Liesbet Geris. Executive Director of the VPH Institute.www.ema.europa.eu/en/documents/presentation/presentation-artificial-intelligence-digital-twins-promise-personalised-medicine-liesbet-geris_en.pdf [accesso del 04.02.2024]
 
EMA 2024. Big Data Workplan2023-2025. https://www.ema.europa.eu/en/documents/work-programme/workplan-2023-2025-hma-ema-joint-big-data-steering-group_en.pdf [accesso
del 04.02.2024]
 
EMA 2024 BDSG. Big Data Steering Group (BDSG): 2023 report. https://www.ema.europa.eu/en/documents/report/big-data-steering-group-bdsg-2023-report_en.pdf [accesso del 04.02.2024]
 
EMA/532436/2020. GDPR and the secondary use of health data. https://www.ema.europa.eu/en/documents/report/report-workshop-application-general-data-protection-regulation-gdpr-area-health-and-secondary-use-data-medicines-and-public-health-purposes_en.pdf [accesso del 4/02/2024]
 
EPICOST. http://www.epicost.it/servizi-40-il_progetto_epicost [accesso del 04.02.2024]
 
EUNETHTA. HTA Core Model®. https://www.eunethta.eu/hta-core-model/ [accesso del 11.03.2024]
 
EU 2016. Directorate-General for Health and Food Safety Health Programme. Study on Big Data in Public Health, Telemedicine and Healthcare. https://health.ec.europa.eu/document/download/a9f77525-d621-48d5-aff9-da0973b3b19b_en
[accesso del 04.02.2024]
 
EU 2018. Policy Department for Economic, Scientific and Quality of Life Policies. Digitalisation and Big Data: Implications for the health sector. https://www.europarl.europa.eu/RegData/ etudes/IDAN/2018/619030/IPOL_IDA(2018)619030_EN.pdf [accesso del 04.02.2024]
 
European Commission. Shaping Europe’s digitalfuture: European Data Governance Act. https://digital-strategy.ec.europa.eu/en/policies/data-governance-act [accesso del 4/02/2024]
 
Farmindustria 2022. Documento Farmindustria sulla rilevanza della Real World Evidence: strumento innovativo per contribuire al miglioramento della governance sanitaria. https://www.
farmindustria.it/app/uploads/2022/11/RWE-Farmindustria-Final-002.pdf [accesso del 04.02.2024]
 
FDA 2018. FRAMEWORK FOR FDA’S REAL_WORLD EVIDENCE PROGRAM. https://www.fda.gov/media/120060/download?attachment [accesso del 04.02.2024]
 
FDA 2023a. Real-World Evidence. https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence [accesso del 04.02.2024]
 
FDA 2023. Facilitating Review of Real-World Data Studies: The Oncology QCARD Initiative. https://www.fda.gov/news-events/fda-voices/facilitating-review-real-world-data-studies-oncology-
qcard-initiative [accesso del 04.02.2024]
 
FDA QCARD. https://www.fda.gov/about-fda/oncology-center-excellence/oncology-quality-characterization-and-assessment-real-world-data-qcard-initiative [accesso del 04.02.2024]
 
Finotello F, Calura E, Risso D, Hautaniemi S, Romualdi C. Editorial: Multi-omic Data Integration in Oncology. Front Oncol. 2020 Sep 15;10:1768.
 
Flatiron. Reimagining the infrastructure of cancer care. https://flatiron.com/ [accesso del 04.02.2024]
 
Geraci J, Bhargava R, Qorri B, Leonchyk P, Cook D, Cook M, Sie F,Pani L. Machine learning hypothesis-generation for patient stratificationand target discovery in rare disease: our experience with Open Science in ALS. Front Comput Neurosci. 2024 Jan 4;17:1199736.
 
Gehring, M., Jommi, C., Tarricone, R., Cirenei, M., & Ambrosio,G. (2015). Towards a more competitive Italy in clinical research:The survey of attitudes towards trial sites in Europe (the SAT-EU
study™). Epidemiology Biostatistics and Public Health, 12(1), 1-9.
 
GIMEMA-ALLIANCE. Fondazione GILEMA ONLUS. https://www.gimema.it/gimema-alliance/ [accesso del 03/03/2024]
 
Governo Italiano. Sanità digitale. https://innovazione.gov.it/italia-digitale-2026/il-piano/sanita-digitale/ [accesso del4/02/2024]
 
HARMONY. European Public-Private Partnership for Big Datain Hematology. https://www.harmony-alliance.eu/ [accesso del04.02.2024]
 
Hernandez-Boussard T, Macklin P, Greenspan EJ, et al. Digital twins for predictive oncology will be a paradigm shift for precision cancer care. Nat Med. 2021 Dec;27(12):2065-2066.
 
Il Sole 24 Ore. 27 Marzo 2023. Ricerca clinica: dall’innovazione benefici per il sistema e solo nell’oncoematologia risparmi potenzialidi 400mln l’anno. Ma l’Italia è ferma all’1,43% del Pil e solo
lo 0,5% è investimento pubblico. https://www.sanita24.ilsole-24ore.com/art/medicina-e-ricerca/2023-03-27/ricerca-clinica-innovazione-benefici-il-sistema-servono-fondi-110636.php?uuid=AEYV9OAD[accesso del 04.02.2024]
 
Inan OT, Tenaerts P, Prindiville SA, et al. Digitizing clinical trials.NPJ Digit Med. 2020 Jul 31;3:101.
ISS 2020. L’impatto economico dei tumori sul sistema sanitario:Il progetto EPICOST.https://www.iss.it/tumori/-/asset_publisher/QFACMpQtWq3G/content/l-impatto-economico-dei-tumori-sul-sistema-sanitario-il-progetto-epicost-1 [accesso del 04.02.2024]
 
Jiang P, Sinha S, Aldape K, Hannenhalli S, Sahinalp C, Ruppin E. Big data in basic and translational cancer research. Nat Rev Cancer. 2022 Nov;22(11):625-639.
 
Jommi C, Armeni P, Costa F, Bertolani A, Otto M. Implementation of Value-based Pricing for Medicines. Clin Ther. 2020 Jan;42(1):15-24.
 
Jommi C, Pantellini F, Stagi L, Verykiou M, Cavazza M. The economic impact of compassionate use of medicines. BMC Health Serv Res. 2021 Dec 4;21(1):1303.
 
Jommi C, Bertolani A, Armeni P, Costa F, Otto M. Pharmaceutical pricing and managed entry agreements: An exploratory study on future perspectives in Europe. Health Policy and Technology
12 (2023) 100771.
 
KCE - Belgian Health Care Knowledge Centre 2018. Use of patient reported outcome and experience measures in patient care and policy. https://kce.fgov.be/sites/default/files/2021-11/KCE_303C_Patient_reported_outcomes_Short_Report_0. pdf [accesso del 04.02.2024]
 
Lehne M, Sass J, Essenwanger A, Schepers J, Thun S. Why digital medicine depends on interoperability. NPJ Digit Med. 2019 Aug 20;2:79.
 
Light DW, Warburton R. Demythologizing the high costs of pharmaceutical research. BioSocieties. 2011;6(1):34–50.
 
Liu, F., Panagiotakos, D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol 22, 287 (2022)
 
Maritano S, d’Errico A, Isaevska E, Moccia C, Moirano G. Esposoma: un nuovo modo di studiare le complesse relazioni
tra Ambiente e Salute. 2021. https://www.cpo.it/workspace/files/scheda-rias_exposoma-60efefcfca216.pdf [accesso del
04.02.2024]
 
Maruszczyk, K.,Aiyegbusi, O.L., Torlinska, B. et al. Systematic review of guidance for the collection and use of patient-reported
outcomes in real-world evidence generation to support regulation, reimbursement and health policy. J Patient Rep Outcomes
6, 57 (2022).
 
Marx V. Method of the Year: spatially resolved transcriptomics. NatMethods. 2021 Jan;18(1):9-14. doi: 10.1038/s41592-
020-01033-y. Erratum in: Nat Methods. 2021 Feb;18(2):219.
 
Messiou C, Lee R, Salto-Tellez M. Multimodal analysis and the oncology patient: Creating a hospital system for integrated
diagnostics and discovery. Comput Struct Biotechnol J. 2023 Sep 15;21:4536-4539.
 
Montouchet C, Thomas M, Anderson J, Foster S. The Oncology Data Landscape in Europe: Report [commissioned by EFPIA -
European Federation of Pharmaceutical Industries and Associations];2018.
 
NIH - National Cancer Institute 2020. It Takes a Village: The Value of Collaboration in Genomic Cancer Studies. https://datascience. cancer.gov/news-events/blog/it-takes-village-value-collaboration-genomic-cancer-studies [accesso del 04.02.2024]
 
Panesar A. Machine learning and AI for healthcare. Big data for improved health outcomes. Coventry: Apress 2019.
 
Pastorino R, De Vito C, Migliara G, et ao. Benefits and challenges of Big Data in healthcare: an overview of the European initiatives. Eur J Public Health. 2019 Oct 1;29(Supplement_3):23-27.An Immune System “GPS” Uncovers Pathways to Treat Diseases. https://www.pfizer.com/news/articles/an_immune_system_gps_uncovers_pathways_to_treat_diseases[accesso del 04.02.2024]
 
Piano Oncologico Nazionale: documento di pianificazione e indirizzo per la prevenzione e il contrasto del cancro 2023-2027.
Ministero della Salute. https://www.salute.gov.it/imgs C_17_pubblicazioni_3291_allegato.pdf [accesso del 04.02.2024]
 
Piciocchi A, Cipriani M, Messina M, Marconi G, Arena V, Soddu S, Crea E, Valeria Feraco M, Ferrante M, la Sala E, Fazi P, Buccisano F, Martinelli G, Venditti A, Vignetti M. P495: UNLOCKING THE POTENTIAL OF SYNTHETIC PATIENTS FOR ACCELERATING CLINICAL TRIALS: RESULTS OF THE FIRST GIMEMA EXPERIENCE. Hemasphere. 2023 Aug 8;7(Suppl ):e4536536.
 
PIONEER - The European Network of excellence for Big Data in prostate cancer. https://prostate-pioneer.eu/ [accesso del
04.02.2024]
 
Piovani D, Bonovas S. Real World-Big Data Analytics in Healthcare. Int J Environ Res Public Health. 2022 Sep
16;19(18):11677.
 
PNRR. Rafforzamento dell’infrastruttura tecnologica e degli strumenti per la raccolta, l’elaborazione, l’analisi dei dati e la simulazione. https://www.italiadomani.gov.it/it/Interventi/investimenti/rafforzamento-dell-infrastruttura-tecnologica-e-degli-strumenti-per-la-raccolta-l-elaborazione.html [accesso del 4/02/2024]
 
PRIME:priority medicines. https://www.ema.europa.eu/en/human-regulatory-overview/research-and-development/prime-priority-medicines [accesso del 04.02.2024]
 
Provvedimento n. 146 del 5 giugno 2019. Provvedimentorecante le prescrizioni relative al trattamento di categorie particolari
di dati, ai sensi dell’art. 21, comma 1 del d.lgs. 10 agosto 2018, n. 101. [doc. web n. 9124510].
 
QuotidianoSanita’ 2022. sservatoriosulla condizione assistenziale dei malati oncologici. 14° Rapporto sulla condizione assistenziale dei malati oncologici. https://www.quotidianosanita.it/allegati/allegato1652351383.pdf [accesso del 4/02/2024]
 
QuotidianoSanita’ 2023. Osservatorio sulla condizione assistenziale dei malati oncologici. 15° Rapporto sulla condizione assistenziale dei malati oncologici. https://www.quotidianosanita.it/allegati/allegato1684414502.pdf [accesso del 4/02/2024]
 
Regolamento EU 2016/679 arricchito con riferimenti ai Considerando Aggiornato alle rettifiche pubblicate sulla Gazzetta Ufficiale dell’Unione europea 127 del 23 maggio 2018. https://www.garanteprivacy.it/documents/10160/0/Regolamento+UE+2016+679.+Arricchito+con+riferimenti+ai+Considerando+Aggiornato+alle+rettifiche+pubblicate+-sulla+Gazzetta+Ufficiale++dell%27Unione+europea+127+-del+23+maggio+2018 [accesso del 4/02/2024]
 
Regolamento (UE) 2022/868. Governance europea dei dati. https://eur-lex.europa.eu/legal-content/IT/TXT/PDF/?uri=CELEX:
32022R0868 [accesso del 4/02/2024]Rennane S, Baker L, Mulcahy A. Estimating the Cost of Industry Investment in Drug Research and Development: A Review of Methods and Results. Inquiry. 2021 Jan-Dec;58:469580211059731
 
Rivera DR, Kluetz PG. Facilitating Review of Real-World Data Studies: The Oncology QCARD Initiative. FDA 2023. https://www.
fda.gov/news-events/fda-voices/facilitating-review-real-world-data-studies-oncology-qcard-initiative[accesso del 04.02.2024]
 
Schlander M, Hernandez-Villafuerte K, Cheng CY, Mestre-Ferrandiz J, Baumann M. How Much Does It Cost to Research and
Develop a New Drug? A Systematic Review and Assessment. Pharmacoeconomics. 2021 Nov;39(11):1243-1269.
 
Sheng B, Wang Z, Qiao Y, et al. Detecting latent topics and trends of digital twins in healthcare: A structural topic model-based systematic review. Digit Health. 2023 Oct 12;9:20552076231203672.
 
 
Steinhubl SR, Wolff-Hughes DL, Nilsen W, Iturriaga E, Califf RM.Digital clinical trials: creating a vision for the future. NPJ Digit
Med. 2019 Dec 12;2:126.
 
Subrahmanya SVG, et al. The role of data science in healthcare advancements: applications, benefits, and future prospects. Irish
J Med Sci. 2022 Aug;191(4):1473-1483.
 
Sultana J, Addis A, Braga M, Campomori A, Capuano A, Corrao G, Gini R, Mazzaglia G, Patarnello F, Petrini C, Pierini A, Pippo L,
Popoli P, Russo P, Scondotto G, Caputi AP, Trifirò G. What can real-world evidence contribute to regulatory science in pre- and
post-marketing setting? Pharmadvances2020; 02: 51-58
 
Swanson K, Wu E, Zhang A, Alizadeh AA, Zou J. From patterns to patients: Advances in clinical machine learning for cancer diagnosis, prognosis, and treatment. Cell. 2023 Apr 13;186(8):1772-1791.
 
Taylor Wessing. Towards big data and AI in health: the lawful basis for using patient data to build digital health products.
June 2022. https://www.taylorwessing.com/en/insights-and-events/insights/2022/05/towards-big-data-and-ai-in-health-thelawful-basis [accesso del 4/02/2024]
 
TEHDAS 2023. Advancing data sharing to improve health for all in Europe. Main findings of joint action towards the European
health data space 2021–2023. https://tehdas.eu/results/eu-wide- collaboration-needed-to-optimise-health-data-use-for-research-and-innovation/ [accesso del 04.02.2024]
 
The Cancer Genome Atlas Program (TCGA). https://www.cancer.gov/ccg/research/genome-sequencing/tcga[accesso del
04.02.2024]
 
Toscano F, Vera A, Kim E, Golinelli D, Vila-Reyes H, Bteich F, Schernberg A, Seban RD, Yeh R, Dercle L. The Role of Cost-Effectiveness Analysis in Patient-Centered Cancer Care in the Era of Precision Medicine. Cancers(Basel). 2021 Aug 25;13(17):4272.
 
Wang X, Dormont F, Lorenzato C, Latouche A, Hernandez R, Rouzier R. Current perspectives for external control arms in
oncology clinical trials: Analysis of EMA approvals 2016-2021. J Cancer Policy. 2023 Mar;35:100403.
 
World Health Organization 2023 . Regulatory considerations on artificial intelligence for health. https://iris.who.int/
handle/10665/373421 [accesso del 04.02.2024]
 
Zhang Z, Wei X. Artificial intelligence-assisted selection and efficacy prediction of antineoplastic strategies for precision cancer therapy. Semin Cancer Biol. 2023 May;90:57-72.